Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Zacks Research raised their Q1 2026 earnings estimates for shares of Prestige Consumer Healthcare in a report issued on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the company will earn $1.00 per share for the quarter, up from their prior forecast of $0.97. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q2 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.32 EPS, Q2 2027 earnings at $1.23 EPS, Q4 2027 earnings at $1.27 EPS and FY2027 earnings at $5.02 EPS.
Other equities analysts have also issued research reports about the company. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Oppenheimer upped their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Finally, Wall Street Zen raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 17th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.
Check Out Our Latest Report on PBH
Prestige Consumer Healthcare Trading Down 0.6%
PBH traded down $0.50 during trading on Monday, reaching $84.99. 250,170 shares of the company's stock were exchanged, compared to its average volume of 298,313. The company's fifty day moving average price is $83.60 and its 200-day moving average price is $82.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The firm has a market capitalization of $4.20 billion, a PE ratio of 19.90, a P/E/G ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare has a fifty-two week low of $63.02 and a fifty-two week high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm earned $1.02 EPS.
Hedge Funds Weigh In On Prestige Consumer Healthcare
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Kayne Anderson Rudnick Investment Management LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $84,932,000. Raymond James Financial Inc. acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $42,593,000. Norges Bank bought a new stake in Prestige Consumer Healthcare in the fourth quarter worth approximately $40,009,000. Bessemer Group Inc. increased its stake in shares of Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company's stock valued at $23,041,000 after acquiring an additional 292,144 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock valued at $113,635,000 after purchasing an additional 261,537 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is owned by company insiders.
About Prestige Consumer Healthcare
(
Get Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
